Assessing when to initiate anticoagulation in atrial fibrillation is not improved by including gender, says the ESC in their ...
Top biopharma company selects the next generation of CRM for life sciences as its commercial foundation for future expansion ...
More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the ...
Medpage Today on MSN6d
Zepbound's Weight Loss, Cardiometabolic Benefits Hold Up at 3 YearsSAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...
Top biopharma company selects the next generation of CRM for life sciences as its commercial foundation for future expansion and launches BARCELONA, Spain, Nov. 14, 2024 /PRNewswire/ -- Veeva Systems ...
More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1·DRD is a growing epidemic ...
The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...
Boehringer Ingelheim and MTM Vision join forces to combat vision loss from diabetes: Ingelheim, Germany Wednesday, November 13, 2024, 10:00 Hrs [IST] Boehringer Ingelheim and the ...
Abdulla also aims to further strengthen relationships with regional governments and key healthcare stakeholders to ensure ...
Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...
SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback